Published in J Pharmacol Exp Ther on November 21, 2003
The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol (2013) 1.88
Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J (2009) 1.78
Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol (2007) 1.77
Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol (2009) 1.39
Pore dilation occurs in TRPA1 but not in TRPM8 channels. Mol Pain (2009) 1.34
The P2X(7) receptor-pannexin connection to dye uptake and IL-1beta release. Purinergic Signal (2009) 1.32
Molecular and functional properties of P2X receptors--recent progress and persisting challenges. Purinergic Signal (2012) 1.31
Permeation and block of TRPV1 channels by the cationic lidocaine derivative QX-314. J Neurophysiol (2013) 1.14
Activation of ERK1/2 by extracellular nucleotides in macrophages is mediated by multiple P2 receptors independently of P2X7-associated pore or channel formation. Br J Pharmacol (2006) 1.08
Species and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function. Br J Pharmacol (2006) 1.03
Selective P2X(7) receptor antagonists for chronic inflammation and pain. Purinergic Signal (2008) 0.97
Physiological and pathological functions of P2X7 receptor in the spinal cord. Purinergic Signal (2009) 0.95
Identification of Thr283 as a key determinant of P2X7 receptor function. Br J Pharmacol (2006) 0.95
Many ways to dilate the P2X7 receptor pore. Br J Pharmacol (2011) 0.95
ATP-P2X7 receptor signaling controls basal and TNFα-stimulated glial cell proliferation. Glia (2012) 0.94
Externally triggered egress is the major fate of Toxoplasma gondii during acute infection. J Immunol (2009) 0.92
Large-conductance channel formation mediated by P2X7 receptor activation is regulated through distinct intracellular signaling pathways in peritoneal macrophages and 2BH4 cells. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.89
A novel role for P2X7 receptor signalling in the survival of mouse embryonic stem cells. Cell Signal (2011) 0.88
Cardiomyocyte ATP release through pannexin 1 aids in early fibroblast activation. Am J Physiol Heart Circ Physiol (2012) 0.87
P2X7 receptor activation induces reactive oxygen species formation in erythroid cells. Purinergic Signal (2012) 0.87
Effects of toxic cellular stresses and divalent cations on the human P2X7 cell death receptor. Mol Vis (2008) 0.87
Inhibition of neuronal cell death after retinoic acid-induced down-regulation of P2X7 nucleotide receptor expression. Mol Cell Biochem (2009) 0.81
CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation. Purinergic Signal (2013) 0.79
Lipopolysaccharide inhibits the channel activity of the P2X7 receptor. Mediators Inflamm (2011) 0.77
Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia. J Vasc Surg (2016) 0.76
Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors. FEBS Lett (2015) 0.75
Subfailure Overstretch Injury Leads to Reversible Functional Impairment and Purinergic P2X7 Receptor Activation in Intact Vascular Tissue. Front Bioeng Biotechnol (2016) 0.75
P2X7 Receptor Induces Tumor Necrosis Factor-α Converting Enzyme Activation and Release to Boost TNF-α Production. Front Immunol (2017) 0.75
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A (2007) 2.60
A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther (2006) 2.06
Purine and pyrimidine (P2) receptors as drug targets. J Med Chem (2002) 2.05
Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain (2006) 1.55
P2X receptors as drug targets. Mol Pharmacol (2012) 1.43
Molecular determinants of species-specific activation or blockade of TRPA1 channels. J Neurosci (2008) 1.42
Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br J Pharmacol (2003) 1.42
Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol (2009) 1.39
Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem (2006) 1.36
Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. Pain (2011) 1.34
Pore dilation occurs in TRPA1 but not in TRPM8 channels. Mol Pain (2009) 1.34
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther (2005) 1.33
Painful purinergic receptors. J Pharmacol Exp Ther (2007) 1.33
Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain (2002) 1.27
Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain. Behav Brain Res (2005) 1.25
Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem (2005) 1.24
Transient receptor potential A1 mediates an osmotically activated ion channel. Eur J Neurosci (2008) 1.23
Functional expression of P2X7 receptors in non-neuronal cells of rat dorsal root ganglia. Brain Res (2005) 1.14
Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management. J Med Chem (2008) 1.10
Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res Rev (2008) 1.08
TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain (2002) 1.08
Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res (2008) 1.06
TRPV1b overexpression negatively regulates TRPV1 responsiveness to capsaicin, heat and low pH in HEK293 cells. J Neurochem (2006) 1.05
Enhanced thermal avoidance in mice lacking the ATP receptor P2X3. Pain (2005) 1.02
Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury. Brain Res (2004) 1.02
Alteration of dorsal root ganglion P2X3 receptor expression and function following spinal nerve ligation in the rat. Exp Brain Res (2002) 1.01
Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. J Neurophysiol (2003) 0.99
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther (2005) 0.99
The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav Brain Res (2009) 0.99
A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J Pharmacol Exp Ther (2007) 0.97
5,6,7-trisubstituted 4-aminopyrido[2,3-d]pyrimidines as novel inhibitors of adenosine kinase. J Med Chem (2003) 0.97
Selective P2X(7) receptor antagonists for chronic inflammation and pain. Purinergic Signal (2008) 0.97
Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats. J Neurophysiol (2005) 0.96
Contributions of central and peripheral TRPV1 receptors to mechanically evoked and spontaneous firing of spinal neurons in inflamed rats. J Neurophysiol (2008) 0.96
Monosodium iodoacetate-induced joint pain is associated with increased phosphorylation of mitogen activated protein kinases in the rat spinal cord. Mol Pain (2011) 0.95
P2X receptor antagonists for pain management: examination of binding and physicochemical properties. Purinergic Signal (2011) 0.93
Capsaicin causes protein synthesis inhibition and microtubule disassembly through TRPV1 activities both on the plasma membrane and intracellular membranes. Biochem Pharmacol (2007) 0.93
Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597). Mol Pharmacol (2007) 0.93
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem (2004) 0.92
TRPV1-related modulation of spinal neuronal activity and behavior in a rat model of osteoarthritic pain. Brain Res (2010) 0.91
Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists. Bioorg Med Chem (2006) 0.90
A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats. Biochem Pharmacol (2011) 0.90
A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats. Neuropharmacology (2010) 0.90
Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats. Brain Res (2009) 0.89
[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology (2008) 0.89
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem (2006) 0.88
Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists. Bioorg Med Chem Lett (2011) 0.88
Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain. J Med Chem (2009) 0.87
Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice. Eur J Pharmacol (2012) 0.87
Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature. J Pharmacol Exp Ther (2012) 0.87
Synthesis and biological evaluation of pteridine and pyrazolopyrimidine based adenosine kinase inhibitors. Bioorg Med Chem Lett (2004) 0.86
Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain. Bioorg Med Chem (2010) 0.86
Modulation of human TRPV1 receptor activity by extracellular protons and host cell expression system. Eur J Pharmacol (2006) 0.86
Acidification of rat TRPV1 alters the kinetics of capsaicin responses. Mol Pain (2005) 0.86
Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes. J Med Chem (2006) 0.86
Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models. J Pain (2008) 0.86
The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats. Brain Res (2004) 0.86
Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R). Bioorg Med Chem Lett (2008) 0.85
Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists. J Med Chem (2008) 0.85
Increased WDR spontaneous activity and receptive field size in rats following a neuropathic or inflammatory injury: implications for mechanical sensitivity. Neurosci Lett (2004) 0.85
TRPV1 antagonist, A-889425, inhibits mechanotransmission in a subclass of rat primary afferent neurons following peripheral inflammation. Synapse (2011) 0.84
Endogenous opioid mechanisms partially mediate P2X3/P2X2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain. Br J Pharmacol (2005) 0.84
5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors. Bioorg Med Chem (2005) 0.84
Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5). Biochem Pharmacol (2004) 0.84
(L)-Phenylglycine, but not necessarily other alpha2delta subunit voltage-gated calcium channel ligands, attenuates neuropathic pain in rats. Pain (2006) 0.84
Design, synthesis, and structure-activity relationship of 6-alkynylpyrimidines as potent adenosine kinase inhibitors. J Med Chem (2002) 0.84